WordNet

the branch of genetics that studies the genetically determined variations in responses to drugs in humans or laboratory organisms

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 薬理ゲノム学の概要 overview of pharmacogenomics
2. オーダーメイド医療 personalized medicine
3. 成人における抗癌剤の投与 dosing of anticancer agents in adults
4. ワルファリンおよびその他のビタミンK拮抗剤の治療使用 therapeutic use of warfarin and other vitamin k antagonists
5. 遺伝性疾患の基本原則 basic principles of genetic disease

English Journal

[Pharmacogenetical aspects of clinical anaesthesiology].

Burlev AV, Shifman EM.AbstractThis survey of literature highlights the issues of pharmacogenetics and pharmacogenomics, the nomenclature of polymorphisms and the major clinically significant polymorphisms for the classes of medications which are most widespread in clinical anaesthesia. 53 data sources has been analyzed, including the polymorphism data base of National Center for Biotechnological Information (USA). Nowadays, choosing a medication do not provide for a individual genetic variability. It is possible that some of the drugs are potent to cause severe adverse effects or ineffective in certain subclasses of population due to unfavourable effectiveness/toxicity ratio. As the technology is developing, it is possible in future to treat every genetic subpopulation with a specific medication in order to obtain a target effect. Perhaps, it is too early to expect some immediate results of pharmacogenetics for a daily practice in anaesthesia. Nevertheless, it is possible that progress in genomics will enable a better understanding of those single nucleotide polymorphisms (SNPs) and haplotypes which alter the response to a medication. Those future discoveries will enable the targeting of the anaesthesia medications and personalization of the anaesthesia strategy aimed at improving the surgery outcomes as well as treating the acute and chronic pain according to a genetic profile of the patient.
Anesteziologiia i reanimatologiia.Anesteziol Reanimatol.2010 Nov-Dec;(6):83-6.
This survey of literature highlights the issues of pharmacogenetics and pharmacogenomics, the nomenclature of polymorphisms and the major clinically significant polymorphisms for the classes of medications which are most widespread in clinical anaesthesia. 53 data sources has been analyzed, includin
PMID 21400801

[Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].

Higuchi H.SourceDepartment of Neuropsychiatry, St Marianna Medical University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, 216-8511 Japan. h5higuchi@marianna-u.ac.jp
Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology.Nihon Shinkei Seishin Yakurigaku Zasshi.2010 Apr;30(2):71-6.
In a milnacipran study, ninety-six patients with major depressive disorder were treated with milnacipran, 50-100 mg/day, for 6 weeks. Severity of depression was assessed with the Montgomery and Asberg Depression Rating Scale. The purpose of this study was to determine whether norepinephrine transpor
PMID 20491280

[Clinical pharmacogenetics in the treatment of schizophrenia].

Furukori N.SourceDepartment of Neuropsychiatry, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562 Japan. yasufuru@cc.hirosaki-u.ac.jp
Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology.Nihon Shinkei Seishin Yakurigaku Zasshi.2010 Apr;30(2):65-9.
Numerous investigations on metabolic enzymes, cytochrome P450 (CYP) have been conducted since 1990. In the psychiatric field, CYP2D6, which is a major enzyme involved in the metabolism of antidepressants and antipsychotics, has been focused on. Poor metabolizers (deficit metabolizers) for CYP2D6 are
PMID 20491279